Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which numbing drug works best for dialysis access surgery?

NCT ID NCT07259772

Symptom relief Sponsor: The First People's Hospital of Lianyungang Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two numbing medicines, ropivacaine and lidocaine, in 40 adults with end-stage kidney disease who need surgery to create a blood vessel connection (fistula) for dialysis. Patients are randomly assigned to receive one of the two drugs during surgery, and neither they nor their surgeons know which one is used. Researchers measure pain levels, surgery time, need for extra pain relief, and how well the fistula works over the next 5 years. The goal is to find which drug provides better pain control and may improve long-term surgical success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Apr 2019

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients (aged ≥18 years) scheduled for primary radiocephalic arteriovenous fistula creation * Diagnosed with end-stage renal disease requiring hemodialysis * Willing and able to provide written informed consent Exclusion Criteria: 1. History of arteriovenous fistula on the ipsilateral limb 2. Impaired communication abilities or inability to complete questionnaires due to language barriers, or missing essential data 3. Preoperative ultrasound findings of: * Radial or brachial artery diameter \<1.8 mm * Cephalic vein diameter \<2 mm at the wrist or \<3 mm at the elbow (without tourniquet application) 4. Known allergy to local anesthetics (ropivacaine or lidocaine) 5. Coagulopathy or bleeding disorders 6. Local infection at the planned anesthesia or surgical site 7. Severe peripheral neuropathy or neurological disorders affecting upper limb function 8. Significant thrombosis or severe stenosis in the proximal major veins or central veins of the limb 9. Pregnancy or breastfeeding 10. Participation in another clinical trial within 30 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arteriovenous fistula patency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arteriovenous fistula patency Chronic kidney disease 5D End-stage renal disease (ESRD)

Contacts and locations

Locations

  • Lianyungang First People's Hospital

    Lianyungang, Jiangsu, 222000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.